Behaviour: deteriorated/ disturbed/un‐cooperative · patients with schizophrenia
It is very uncertain whether CHLORPROMAZINE changes behaviour: deteriorated/ disturbed/un‐cooperative compared with PLACEBO (very low certainty).
1 finding from 1 review
Cost of care ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: clinically significant response in global state ‐ by long term ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mental state: 2. Specific‐ Positive symptoms, total score‐ average endpoint scores (SADS‐C‐PD scale, lower = better) · patients with schizophrenia
1 finding from 1 review
Mental state: average score for negative symptoms ‐ by short term Manchester Scale, negative subset endpoint. Scale from: 0 to 20. · patients with schizophrenia
1 finding from 1 review
Mental state: average score for depressive and anxious symptoms ‐ by medium term ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life: average score ‐ by long term ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe adverse effects ‐ medium term ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Safety assessments ‐ medium term ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state ‐ clinical improvement ‐ medium term As defined by each study · patients with schizophrenia
TRIFLUOPERAZINE may leads to higher global state ‐ clinical improvement ‐ medium term As defined by each… compared with PLACEBO (low certainty).
1 finding from 1 review
Global state ‐ relapse or worsening ‐ medium term Numbers of participants experiencing relapse/worsening · patients with schizophrenia
TRIFLUOPERAZINE may leads to lower global state ‐ relapse or worsening ‐ medium term Numbers of… compared with PLACEBO (low certainty).
1 finding from 1 review
Mental state ‐ any clinically significant response in psychotic symptoms (as defined by each study) ‐ medium term Numbers of participants experiencing 'intensified symptoms' · patients with schizophrenia
It is very uncertain whether TRIFLUOPERAZINE changes mental state ‐ any clinically significant response in psychotic… compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
It is very uncertain whether TRIFLUOPERAZINE changes leaving the study early ‐ any reason ‐ medium term Number of… compared with PLACEBO (very low certainty).
1 finding from 1 review
Severe adverse effects ‐ short term Numbers of participants leaving the studies due to severe adverse effects · patients with schizophrenia
It is very uncertain whether TRIFLUOPERAZINE changes severe adverse effects ‐ short term Numbers of participants leaving… compared with PLACEBO (very low certainty).
1 finding from 1 review
Behaviour ‐ any clinically significant agitation or distress ‐ medium term As defined by each study · patients with schizophrenia
It is very uncertain whether TRIFLUOPERAZINE changes behaviour ‐ any clinically significant agitation or distress ‐… compared with PLACEBO (very low certainty).
1 finding from 1 review
Economic outcomes · patients with schizophrenia
1 finding from 1 review
Death: Suicide and natural causes (no data) · patients with schizophrenia
1 finding from 1 review
Global state: no overall improvement (psychiatrist ‐ rated) · patients with schizophrenia
HALOPERIDOL probably leads to lower overall improvement: No marked global improvement Rated by clinician compared with PLACEBO (moderate certainty).
1 finding from 1 review
Not discharged from hospital · patients with schizophrenia
It is very uncertain whether HALOPERIDOL changes not discharged from hospital compared with PLACEBO (very low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
It is very uncertain whether HALOPERIDOL changes relapse compared with PLACEBO (very low certainty).
1 finding from 1 review